

## Teva and Allergan Documents – Annotated Bibliography

In addition to documents in the Archive, the following sources may be useful in understanding the context of the Teva and Allergan litigation settlements.

### Select Background Regarding General Opioid Litigation

- Minhee, C. (2021). [Opioid Settlement Tracker](#).

*Tracks opioid-related litigation to determine whether settlements are being used to support public health efforts. Includes FAQs, timelines, and analysis.*

### Select Background Focused on Teva and Allergan

- Massachusetts Office of the Attorney General. (2022, Nov. 23). [“AG Healey Announces \\$6.6 Billion Nationwide Settlement with Teva and Allergan over Claims of Illegally Marketing Opioids.”](#)

*Outlines Teva and Allergan litigation background and settlement terms.*

- Teva Pharmaceuticals. (2023, June 8). [Teva Concludes Nationwide Opioids Settlement Agreement](#).

*Teva’s statement on the nationwide settlement agreement.*

- Hoffman, Jan. (2022, July 29). [“Allergan Reaches Tentative \\$2.37 Billion Deal to Settle Opioid Suits.”](#) The New York Times. (registration may be required)
- Hoffman, Jan. (2022, July 26). [“Teva Reaches Tentative \\$4.25 Billion Settlement Over Opioids.”](#) The New York Times. (registration may be required)

*Summarizes the separate Teva and Allergan settlement agreements and explains the companies’ relationship.*

- U.S. Senate Committee on Homeland Security & Governmental Affairs. (2018, March 6). [McCaskill: Teva is Stonewalling a Senate Investigation](#).

*Describes U.S. Senator Claire McCaskill’s efforts to investigate the role of opioid manufacturers and distributors in the ongoing opioid public health crisis, and Teva’s resistance to providing information.*

- Knowledge at Wharton. (2015, August 5). [Why Teva Paid \\$40.5 Billion for Allergan’s Generic Business](#). Wharton School of the University of Pennsylvania.

*Explains Teva's history and how acquiring Allergan strengthened its position in the generic market.*

- Krauskopf, L. (2011, May 2). [Teva to buy Cephalon for \\$6.8 billion, tops Valeant](#). Reuters. (registration may be required)

*Reports on Teva's acquisition of Cephalon and how it would enhance Teva's branded drugs business.*